Plain-English translation of NCT06736015 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether myo-inositol and selenium — two natural compounds important for thyroid health — can help slow or prevent the growth of uncertain thyroid nodules. You have a thyroid nodule that your biopsy showed is low-risk but needs careful monitoring, and researchers want to see if this medication might reduce the need for repeated biopsies or surgery by keeping the nodule from growing.
When a thyroid nodule biopsy result is uncertain (classified as TIR3A), patients usually need repeated imaging and biopsies to watch for growth or cancer risk. This trial exists to see whether this treatment could help prevent nodule growth, potentially sparing patients from unnecessary follow-up procedures.
You likely qualify if…
You likely don't qualify if…
If you join, you will either take the daily supplement (myo-inositol and selenium) or receive no treatment, depending on random assignment. The study lasts 6 months, during which you will take the medication as directed and likely have follow-up visits to check your thyroid nodule with ultrasound or biopsy. Researchers will compare whether the supplement group had less nodule growth than the control group.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Italy
Regina Elena Cancer Institute
Enrollment target
~30 participants
Started
October 2024
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Marialuisa Appetecchia, MD
Regina Elena National Cancer Institute - IRCCS IFO
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.